XML 107 R69.htm IDEA: XBRL DOCUMENT
v3.22.1

Business combinations (Details Narrative) - BRL (R$) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 04, 2021 | May 13, 2021 | Apr. 16, 2021 | Apr. 08, 2021 | Mar. 25, 2021 | Jan. 21, 2021 | Nov. 09, 2020 | Nov. 05, 2020 | Nov. 04, 2020 | Nov. 03, 2020 | Oct. 01, 2020 | Jul. 20, 2020 | May 05, 2020 | Jan. 31, 2020 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Nov. 09, 2021 | Jun. 01, 2021
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | R$ 13,030 |  |  |  |
Net revenue |  |  |  | R$ 1,945,000 |  |  |  |  |  |  |  |  |  |  |  | 1,719,371,000 | R$ 1,201,191,000 | R$ 750,630,000 |  |
Income loss before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 273,462,000 | 335,054,000 | R$ 186,937,000 |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,435 |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 926 |  |  |  |
MedPhone Tecnologia em Saude Ltda ("MedPhone") [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction costs |  |  |  |  |  |  |  | R$ 158,000 | R$ 158 |  |  |  |  |  |  |  |  |  |  |
Net revenue |  |  |  |  |  |  |  |  | 49,000 |  |  |  |  |  |  |  |  |  |  |
Income loss before income taxes |  |  |  |  |  |  |  |  | R$ 57 |  |  |  |  |  |  |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 142 |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | R$ 46 |  |  |
I Clinic [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of acquiree |  |  |  |  | The aggregate purchase price of R$191,120 is comprised of: (i) 62.6% was paid in cash, and (ii) 37.4% was settled with Afya's shares on the transaction closing date. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction costs |  |  |  |  |  | R$ 856 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenue |  |  |  |  |  | 16,456,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income loss before income taxes |  |  |  |  |  | R$ 8,250 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,158 |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,320 |  |  |  |
Cliquefarma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  | 100.00% |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of acquiree |  |  | The aggregate purchase price of R$ 22,089 is comprised by: (i) R$ 16,166 paid in cash; (ii) R$3,000 settled with Afya's shares on the transaction closing date; and (iii) an earn-out (“contingent consideration”) of R$ 3,000 is payable in relation to product development. The contingent consideration of R$2,923 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction costs |  |  | R$ 336 |  | R$ 117 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenue |  |  |  |  | 359,000 |  |  |  |  |  |  |  |  |  |  | 3,268,000 |  |  |  |
Income loss before income taxes |  |  |  |  | R$ 1,518 |  |  |  |  |  |  |  |  |  |  | 1,752 |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 105 |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 113 |  |  |  |
Medicinae [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of acquiree |  |  |  |  | The aggregate purchase price of R$9,172 is comprised by: i) R$ 5,600 of which 100% was paid in cash on the transaction closing date; and ii) an earn-out (“contingent consideration”) of up of R$ 4,400 is payable in connection with product development goals for 2021 and revenue achievements for 2022. The contingent consideration of R$3,572 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Harbour [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00%
Description of acquiree |  |  |  | The aggregate purchase price of R$11,278 is comprised by: i) R$ 5,000 of which 100% was paid in cash on the transaction closing date; and ii) an earn-out (“contingent consideration”) of up to R$ 9,000 is payable in connection with product development goals for 2021 and 2022 and revenue achievements for 2023. The contingent consideration of R$6,278 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction costs |  |  |  | R$ 144 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income loss before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 127 |  |  |  |
Revenue of acquiree since acquisition date |  |  |  | R$ 484 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue of combined entity as if combination occurred at beginning of period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 268 |  |  |  |
Shosp [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of acquiree |  | The aggregate purchase price of R$7,901 is comprised by: i) R$ 5,855 was paid in cash; ii) R$ 454 of consideration to be transferred; and iii) an earn-out (“contingent consideration”) of up to R$ 1,793 is payable in relation to product development. The contingent consideration of R$1,592 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction costs |  | R$ 188 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenue |  | 1,376,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income loss before income taxes |  | R$ 448 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 306 |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 82 |  |  |  |
U N I F I P Moc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |
Description of acquiree |  |  |  |  |  |  |  |  |  |  |  |  |  |  | The aggregate purchase price is R$ 328,322 and the total amount was paid in cash. There are 40 additional seats still pending approval, which, if approved by the Ministry of Education, will result in a potential additional payment of up to R$ 50,000. Given the future event that will trigger the potential payout is not under the Company’s control, the probability of such payout cannot be reliably estimated and thus the contingent consideration was not measured at acquisition date. Should the additional seats be approved it will result in additional licenses, which will be measured accordingly if and when approved. |  |  |  |  |
Transaction costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | R$ 177 |  |  |  |  |
Net revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 69,887,000 |  |  |  |  |
Income loss before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  | R$ 19,458 |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 46,150 |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,847 |  |  |  |
U N I G R A N [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of acquiree | The aggregate original purchase price of R$ 626,116 of which 60% was paid in cash on the transaction closing date, and 40% is payable in cash in four equal installments through 2022 to 2025, adjusted by the CDI rate, was adjusted by R$7,160, because of the actual net debt, to R$618,956. There are 82 additional seats still pending approval which, if approved by MEC, will result in a potential additional payment of up to R$90,200. Given the future event that will trigger the potential payout is not under the Company’s control, the probability of such payout cannot be reliably estimated and thus the contingent consideration was not measured at acquisition date. Should the additional seats be approved it will result in additional licenses, which will be measured accordingly if and when approved. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction costs | R$ 10,990 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenue | 123,369,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income loss before income taxes | R$ 33,450 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,456 |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,191 |  |  |  |
P X P R O [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |
Description of acquiree |  |  |  |  |  |  |  |  |  |  | The aggregate purchase price of R$45,622 is comprised by: i) R$ 30,263 was paid in cash; ii) R$ 76 to be paid as price adjustment, iii) R$5,112 settled with Afya's treasury shares on the transaction closing date; and (iv) an earn-out (“contingent consideration”) of R$ 21,000 is payable in relation to revenue achievements. The contingent consideration of R$10,171 is based on the present value of the obligation considering the facts and circumstances at the acquisition date. |  |  |  |  |  |  |  |  |
Transaction costs |  |  |  |  |  |  |  |  |  |  | R$ 264 |  |  |  |  |  |  |  |  |
Net revenue |  |  |  |  |  |  |  |  |  |  | 907,000 |  |  |  |  |  |  |  |  |
Income loss before income taxes |  |  |  |  |  |  |  |  |  |  | R$ 984 |  |  |  |  |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,155 |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | R$ 325 |  |  |  |
Uni Redentor [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |
Description of acquiree |  |  |  |  |  |  |  |  |  |  |  |  |  | The original purchase price of R$214,608, was adjusted by R$4,503 and was comprised by: i) R$114,607 paid in cash on the acquisition date; and ii) R$100,000 is payable in five equal installments from January 2021 to July 2024, adjusted by the CDI rate. The purchase consideration adjustment of R$4,503 was deducted from the first installment due in January 2021. |  |  |  |  |  |
Transaction costs |  |  |  |  |  |  |  |  |  |  |  |  |  | R$ 1,380 |  |  |  |  |  |
Net revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 96,065,000 |  |  |  |  |  |
Income loss before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,952 |  |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,931 |  |  |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | R$ 321 |  |  |  |  |  |
Uni S L [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |
Description of acquiree |  |  |  |  |  |  |  |  |  |  |  |  | The original purchase consideration of R$201,521 was adjusted by R$7,816, of which: (i) 70% is payable in cash on the transaction closing date, and (ii) 30% is payable in cash in three equal installments through 2023, adjusted by the CDI rate. The purchase consideration adjustment of R$7,816 was deducted from the first installment due in May 2021. |  |  |  |  |  |  |
P E B M E D [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |
Description of acquiree |  |  |  |  |  |  |  |  |  |  |  | The original purchase price of R$ 132,900 was adjusted by R$ 30 and was comprised by: i) R$115,339 paid in cash on the acquisition date; and ii) R$ 17,531 was paid with Afya Brazil’s shares which were afterwards contributed to the Company in exchange of issuance of 141,976 of its own shares. |  |  |  |  |  |  |  |
Transaction costs |  |  |  |  |  |  |  |  |  |  |  | R$ 613 | R$ 1,666 |  |  |  |  |  |  |
Net revenue |  |  |  |  |  |  |  |  |  |  |  | 17,535,000 | 113,894,000 |  |  |  |  |  |  |
Income loss before income taxes |  |  |  |  |  |  |  |  |  |  |  | 3,413 | 30,649 |  |  |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  |  |  | 17,452 | 57,477 |  |  |  |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  |  |  |  | 9,455 |  |  |  |  |  |  |
Additional payment made |  |  |  |  |  |  |  |  |  |  |  |  | R$ 80,000 |  |  |  |  |  |  |
[custom:DecreasedInIncomeBeforeIncomeTaxes] |  |  |  |  |  |  |  |  |  |  |  | R$ 1,813 |  |  |  |  |  |  |  |
Faculdade de Ensino Superior da Amazonia Reunida ("FESAR") [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00%
Description of acquiree |  |  |  |  |  |  |  |  |  | The aggregate purchase price was R$260,836, including the CDI rate adjustment from the signing date and the real state of the operation, estimated at R$ 17,397, of which 100% was paid in cash on the closing of the operation. The purchase consideration was adjusted by R$1,569 and was paid on February 25, 2021. |  |  |  |  |  |  |  |  |  |
Net revenue |  |  |  |  |  |  |  |  |  | R$ 6,280,000 |  |  |  |  |  |  |  |  |  |
Income loss before income taxes |  |  |  |  |  |  |  |  |  | 3,751 |  |  |  |  |  |  |  |  |  |
Increase in revenue |  |  |  |  |  |  |  |  |  | 29,113 |  |  |  |  |  |  |  |  |  |
Increase in income before income taxes |  |  |  |  |  |  |  |  |  | R$ 14,918 |  |  |  |  |  |  |  |  |  |
MedPhone Tecnologia em Saude Ltda ("MedPhone") [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00%
Description of acquiree |  |  |  |  |  |  |  |  | The net purchase price was R$6,373 of which 100% was paid in cash on the closing of the operation. The purchase price was adjusted to R$6,409, this price adjustment of R$ 36 was paid on February 2, 2021. |  |  |  |  |  |  |  |  |  |  |
F C M P B [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IfrsStatementLineItems [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |
Description of acquiree |  |  |  |  |  |  | The total net purchase price of R$379,913 was adjusted to R$378,807 and is comprised of (i) R$189,913 paid in cash on the transaction closing date, and (ii) R$188,894 is payable in cash in four equal installments through 2024, adjusted by the CDI rate. |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction costs |  |  |  |  |  |  | R$ 721 |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenue |  |  |  |  |  |  | 10,509,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Income loss before income taxes |  |  |  |  |  |  | R$ 3,570 |  |  |  |  |  |  |  |  |  |  |  |  |

X
- References No definition available. + Details
Name: | afya_AdditionalPaymentMade
Namespace Prefix: | afya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | afya_DecreasedInIncomeBeforeIncomeTaxes
Namespace Prefix: | afya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | afya_IfrsStatementLineItems
Namespace Prefix: | afya_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | afya_IncreaseInIncomeBeforeIncomeTaxes
Namespace Prefix: | afya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | afya_IncreaseInRevenue
Namespace Prefix: | afya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph m -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The description of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_a&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_DescriptionOfAcquiree
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_PercentageOfVotingEquityInterestsAcquired
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The profit (loss) before tax expense or income. [Refer: Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 28 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 23 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard -URIDate 2021-03-24 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 103 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard -URIDate 2021-03-24 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 102 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard -URIDate 2021-03-24 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2021-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ProfitLossBeforeTax
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 28 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 23 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard -URIDate 2021-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 32 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard -URIDate 2021-03-24 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 33 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard -URIDate 2021-03-24 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 34 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard -URIDate 2021-03-24 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 82 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard -URIDate 2021-03-24 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 103 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard -URIDate 2021-03-24 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 102 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard -URIDate 2021-03-24 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2021-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2021-03-24 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph B12 -Subparagraph b -Clause v -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2021-03-24 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph B10 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph q -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_RevenueOfAcquiree
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The revenue of the combined entity as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. [Refer: Business combinations [member]; Revenue] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph q -Clause ii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_q_ii&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_RevenueOfCombinedEntity
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=afya_MedPhoneTecnologiaEmSaudeLtdaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_IClinicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_CliquefarmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_MedicinaeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_HarbourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_ShospMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_UNIFIPMocMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_UNIGRANMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_PXPROMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_UniRedentorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_UniSLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_PEBMEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_FaculdadeDeEnsinoSuperiorDaAmazoniaReunidaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_MedPhoneTecnologiaEmSaudeLtdaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=afya_FCMPBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |